UNLABELLED In response to U.S. Pharmacopeia general chapter <797> standards, a clean room was constructed for our in-house radiopharmacy. Previously, most patient doses were prepared as needed just before injection. Currently, to minimize repeated entries into the clean room, most patient doses are prepared in batches; that is, early morning and noontime preparation of doses to be injected at v...

This article presents Virtual Radiopharmacy Laboratory (VR LAB), a virtual laboratory accessible through the Internet. VR LAB is designed and implemented in the framework of the VirRAD European project. This laboratory represents a 3D simulation of a radio-pharmacy laboratory, where learners, represented by 3D avatars, can experiment on radiopharmacy equipment by carrying out specific learning ...

OPINION article Front. Nucl. Med., 31 July 2023Sec. Radiopharmacy and Radiochemistry Volume 3 - 2023 | https://doi.org/10.3389/fnume.2023.1240162

References .......................................................................... 27 Abstract The vast majority of PET radiopharmaceuticals today are cyclotron produced. Carbon-11 (C), Nitrogen-13 (N), Oxygen-15 (O) products are created for in-house use only due to their short half-lives. The longer half-life of Fluorine-18 means that F-labeled PET radiotracers can be widely distributed. Pr...

The renaissance of Ga radiopharmacy has led to great advances in automation technology. The availability of a highly efficient, reliable, long-lived Ge/Ga generator system along with a well-established coordination chemistry based on bifunctional chelating agents have been the bases of this development in Ga radiopharmacy. Syntheses of Ga peptides were originally performed by manual or semiauto...

This paper discusses the development of virtual communities and especially e-learning communities. In particular, this paper is inspired by VirRAD European project, and presents the intermediate results that have raised from the definition of this virtual radiopharmacy community.

This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of new diagnostic and therapeutic radiopharmaceuticals (RP) that are not approved (i.e., not having a marketing authorization or a monograph in the European Pharmacopoeia), excluding endogenous and ubiquitous substances in humans. This pape...